Skip to main content

Table 2 Characteristics of patients in the troponin substudy

From: Cardiac ischemia in patients with septic shock randomized to vasopressin or norepinephrine

Variable

Vasopressin

(n= 65)

Norepinephrine

(n= 56)

Age, years

62.9 (51.2, 73.6)

65.5 (50.8, 76.1)

Male sex, n (%)

43 (66)

42 (75)

Surgical patient, n (%)

25 (39)

25 (45)

APACHE II

28.1 (8.0)

29.2 (7.3)

Preexisting conditions, n (%)

    Ischemic heart disease

    Chronic obstructive pulmonary disease

    Chronic renal failure

    Diabetes

    Liver disease

    Cancer

    Solid-organ transplant

    Corticosteroid use

    Recent trauma

9 (14)

6 (9)

8 (12)

13 (20)

12 (18)

17 (26)

4 (6)

9 (14)

1 (2)

8 (14)

11 (20)

9 (16)

13 (23)

9 (16)

13 (23)

5 (9)

8 (14)

3 (5)

New organ failure at randomization, n (%)

    Cardiovascular

    Respiratory

    Renal

    Hematology/coagulation

    Neurologic

65 (100)

58 (89)

43 (66)

20 (31)

21 (32)

56 (100)

50 (89)

41 (73)

13 (23)

18 (32)

Number of organ dysfunctions at randomization

3.0 (2.0, 3.0)

3.0 (2.0, 4.0)

Source of infection, n (%)

    Lung

    Abdomen

    Othera

28 (43)

19 (29)

18 (28)

28 (50)

16 (29)

12 (21)

Hemodynamic variables at randomization

    Systolic blood pressure (mm Hg)

    Mean arterial pressure (mm Hg)

    Arterial pH

    Serum lactate (mM)

110.0 (98.0, 118.0)

72.0 (67.0, 77.0)

7.34 (7.3, 7.4)

2.3 (1.5, 3.6)

105.0 (95.0, 114.0)

70.0 (65.0, 75.0)

7.36 (7.3, 7.4)

2.2 (1.6, 4.1)

Vasoactive drug dosages at randomization

    Norepinephrine (μg/min)

    Epinephrine (μg/min)

    Dopamine (μg/kg/min)

    Dobutamine (μg/kg/min)

    Phenylephrine (μg/min)

14.9 (9.1, 26.6)

30.0 (30.0, 30.0)

3.1 (3.0, 6.0)

6.3 (2.5, 12.5)

66.5 (31.1, 133.2)

18.1 (10.6, 30.0)

25.2 (8.4, 42.0)

8.2 (4.0, 17.0)

7.5 (2.5, 10.0)

104.7 (43.0, 134.5)

Days alive free of mechanical ventilation (first 28 days)

0.5 (0.0, 17.0)

1.0 (0.0, 16.0)

ICU stay,b days

11.5 (6.0, 26.0)

13.0 (6.0, 12.0)

Hospital stay,b days

26.5 (10.5, 74.0)

37.5 (18.5, 89.5)

28-day mortality,c n (%)

27 (42)

24 (43)

90-day mortality,c n (%)

31 (48)

32 (57)

  1. Baseline characteristics and outcomes of patients randomized to vasopressin and norepinephrine. Continuous variables are presented as median and interquartile range. APACHE II is expressed as mean and standard deviation. APACHE II, Acute Physiology and Chronic Health Evaluation II; ICU, intensive care unit. aOther sites of infection included blood, skin, central nervous system, bones and joints, cardiac system, and reproductive organs. bCensored at day 90 if patient did not die or was not discharged prior to day 90. ICU and hospital stay are from time of admission to the ICU. cOutcome of one patient in the vasopressin group was unknown and excluded from the calculations.
Back to article page

Critical Care

ISSN: 1364-8535